ZFIN ID: ZDB-FISH-150901-8139
Fish name: mitfaw2/w2; mpv17a9/a9
Genotype: mitfaw2/w2; mpv17a9/a9
Targeting Reagent: none
HUMAN DISEASE MODELED by mitfaw2/w2; mpv17a9/a9
Human Disease Conditions Citations
acute myeloid leukemia cancer xenotransplantation Khan et al., 2018
abdominal obesity-metabolic syndrome high fat Misselbeck et al., 2019
high cholesterol Misselbeck et al., 2019
gastric adenocarcinoma cancer xenotransplantation Xu et al., 2019
cancer cancer xenotransplantation Arumuggam et al., 2017
cancer xenotransplantation Corkery et al., 2017
cancer xenotransplantation Leung et al., 2017
cancer xenotransplantation Diamantopoulou et al., 2017
cancer xenotransplantation Paul et al., 2015
bacterial meningitis bacterial treatment by injection: Streptococcus pneumoniae van der Spek et al., 2018
bacterial infectious disease bacterial treatment by injection: Pseudomonas aeruginosa Otero-Asman et al., 2020
melanoma cancer xenotransplantation Pekkonen et al., 2018
gamma ray, cancer xenotransplantation Dang et al., 2016
multiple myeloma cancer xenotransplantation Lin et al., 2016
GENE EXPRESSION
Gene expression in mitfaw2/w2; mpv17a9/a9
Reporter gene expression No data available
PHENOTYPE
Phenotype in mitfaw2/w2; mpv17a9/a9
Phenotype Conditions Figures
blood vessel lipid increased amount, abnormal high cholesterol Fig. 8 with imageFig. S11 from Misselbeck et al., 2019
blood vessel lipid increased amount, abnormal high fat Fig. 8 with imageFig. S11 from Misselbeck et al., 2019
equilibrioception decreased process quality, abnormal chemical treatment by environment: oxidopamine, chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 3 from Murcia et al., 2016
equilibrioception decreased process quality, abnormal chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
equilibrioception decreased process quality, abnormal chemical treatment by environment: 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Fig. 2 from Murcia et al., 2016
equilibrioception decreased process quality, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester hydrochloride Fig. 2 from Murcia et al., 2016
equilibrioception decreased process quality, abnormal chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 1Fig. 2Fig. 5 from Murcia et al., 2016
equilibrioception process quality, ameliorated chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
equilibrioception process quality, ameliorated chemical treatment by environment: 1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
equilibrioception process quality, ameliorated chemical treatment by environment: L-dopa, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 5 from Murcia et al., 2016
gut adenocarcinoma decreased size, abnormal chemical treatment by environment: 5-fluorouracil, cancer xenotransplantation, chemical treatment by environment: tyrosine kinase inhibitor Fig. 2 with image from Xu et al., 2019
gut adenocarcinoma decreased size, abnormal cancer xenotransplantation, chemical treatment by environment: tyrosine kinase inhibitor, chemical treatment by environment: paclitaxel Fig. 2 with image from Xu et al., 2019
gut apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: methyl beta-cyclodextrin Fig. 5 with image from Abu-Siniyeh et al., 2016
gut apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: 7-ketocholesterol Fig. 5 with image from Abu-Siniyeh et al., 2016
gut carcinoma increased amount, abnormal cancer xenotransplantation Fig. 4 from Khan et al., 2018
intestinal epithelium lipid increased amount, abnormal high cholesterol Fig. 8 with imageFig. S11 from Misselbeck et al., 2019
intestinal epithelium lipid increased amount, abnormal high fat Fig. 8 with imageFig. S11 from Misselbeck et al., 2019
intestine intestinal intra-epithelial neoplasia neoplastic, abnormal cancer xenotransplantation Fig. 6 from Khan et al., 2018
iridophore absent, abnormal standard conditions Fig. 1 with image from D'Agati et al., 2017
kidney epithelial cell apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: 7-ketocholesterol Fig. 5 with image from Abu-Siniyeh et al., 2016
kidney epithelial cell apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: methyl beta-cyclodextrin Fig. 5 with image from Abu-Siniyeh et al., 2016
leukocyte migration involved in immune response increased occurrence, abnormal bacterial treatment by injection: Mycobacterium marinum M Fig. 8 with image from Phan et al., 2018
liver apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: 7-ketocholesterol Fig. 5 with image from Abu-Siniyeh et al., 2016
liver apical plasma membrane ab1-prkcz labeling decreased amount, abnormal chemical treatment: methyl beta-cyclodextrin Fig. 5 with image from Abu-Siniyeh et al., 2016
melanocyte absent, abnormal standard conditions Fig. 1 with image from D'Agati et al., 2017
pericardial cavity melanoma present, abnormal cancer xenotransplantation Fig. 7 with image from Pekkonen et al., 2018
post-vent region lipid increased amount, abnormal high cholesterol Fig. 8 with image from Misselbeck et al., 2019
post-vent region lipid increased amount, abnormal high fat Fig. 8 with image from Misselbeck et al., 2019
swimming decreased process quality, abnormal chemical treatment by environment: oxidopamine, chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 3 from Murcia et al., 2016
swimming decreased process quality, abnormal chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 1Fig. 2Fig. 5 from Murcia et al., 2016
swimming decreased process quality, abnormal chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
swimming decreased process quality, abnormal chemical treatment by environment: 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Fig. 2 from Murcia et al., 2016
swimming decreased process quality, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester hydrochloride Fig. 2 from Murcia et al., 2016
swimming process quality, ameliorated chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
swimming process quality, ameliorated chemical treatment by environment: L-dopa, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 5 from Murcia et al., 2016
swimming process quality, ameliorated chemical treatment by environment: 1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
thigmotaxis decreased process quality, abnormal chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 1Fig. 2Fig. 5 from Murcia et al., 2016
thigmotaxis decreased process quality, abnormal chemical treatment by environment: oxidopamine, chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 3 from Murcia et al., 2016
thigmotaxis decreased process quality, abnormal chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
thigmotaxis decreased process quality, abnormal chemical treatment by environment: N(gamma)-nitro-L-arginine methyl ester hydrochloride Fig. 2 from Murcia et al., 2016
thigmotaxis decreased process quality, abnormal chemical treatment by environment: 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one Fig. 2 from Murcia et al., 2016
thigmotaxis process quality, ameliorated chemical treatment by environment: 17beta-estradiol, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
thigmotaxis process quality, ameliorated chemical treatment by environment: L-dopa, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 5 from Murcia et al., 2016
thigmotaxis process quality, ameliorated chemical treatment by environment: 1,1-bis(2-aminoethyl)-2-hydroxy-3-oxotriazane, chemical treatment by environment: oxidopamine Fig. 3 from Murcia et al., 2016
whole organism srebf1 expression amount, ameliorated high fat, chemical treatment by environment: ibrutinib Fig. 9 with image from Misselbeck et al., 2019
whole organism il1b expression amount, ameliorated high fat, chemical treatment by environment: ibrutinib Fig. 9 with image from Misselbeck et al., 2019
whole organism decreased life span, abnormal chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 4 from Murcia et al., 2016
whole organism decreased life span, abnormal chemical treatment by environment: oxidopamine Fig. 4 from Murcia et al., 2016
whole organism decreased life span, abnormal cancer xenotransplantation Fig. 5 from Khan et al., 2018
whole organism decreased life span, abnormal bacterial treatment by injection: Pseudomonas aeruginosa, hypotonic Fig. 3 from Huang et al., 2018
whole organism decreased life span, abnormal cancer xenotransplantation Fig. 1 from Banasavadi-Siddegowda et al., 2017
whole organism decreased life span, abnormal bacterial treatment by injection: Salmonella enterica subsp. enterica serovar Typhimurium Fig. 4 from Tyrkalska et al., 2019
whole organism decreased life span, abnormal bacterial treatment by injection: Pseudomonas aeruginosa Figure 2 with image from Otero-Asman et al., 2020
whole organism decreased life span, exacerbated isotonic, bacterial treatment by injection: Pseudomonas aeruginosa Fig. 3 from Huang et al., 2018
whole organism srebf1 expression increased amount, abnormal high fat Fig. 8 with image from Misselbeck et al., 2019
whole organism Ab2-gata1a labeling increased amount, abnormal chemical treatment by environment: EC 3.4.22.36 (caspase-1) inhibitor Fig. 7 from Tyrkalska et al., 2019
whole organism il1b expression increased amount, abnormal isotonic, bacterial treatment by injection: Pseudomonas aeruginosa Fig. 4 from Huang et al., 2018
whole organism il1b expression increased amount, abnormal bacterial treatment by injection: Pseudomonas aeruginosa, hypotonic Fig. 4 from Huang et al., 2018
whole organism il1b expression increased amount, abnormal high fat Fig. 8 with image from Misselbeck et al., 2019
whole organism life span, ameliorated chemical treatment by environment: oxidopamine, chemical treatment by environment: EC 1.14.13.39 (nitric oxide synthase) inhibitor Fig. 4 from Murcia et al., 2016
whole organism life span, ameliorated chemical treatment by environment: EC 2.1.1.* (methyltransferases) inhibitor, cancer xenotransplantation Fig. 1 from Banasavadi-Siddegowda et al., 2017
whole organism glioblastoma present, abnormal chemical treatment by environment: EC 2.1.1.* (methyltransferases) inhibitor, cancer xenotransplantation Fig. 1 from Banasavadi-Siddegowda et al., 2017
whole organism melanoma ab7-mapk labeling decreased amount, abnormal chemical treatment by gavage: vemurafenib, gamma ray, cancer xenotransplantation Fig. 2 with image from Dang et al., 2016
whole organism melanoma increased amount, abnormal cancer xenotransplantation Fig. 1 from Kim et al., 2017
whole organism melanoma increased amount, abnormal gamma ray, cancer xenotransplantation Fig. 2 with imageFig. 3 with imageFig. 4 with image from Dang et al., 2016
whole organism melanoma size, ameliorated chemical treatment by gavage: vemurafenib, gamma ray, cancer xenotransplantation Fig. 2 with imageFig. 3 with imageFig. 4 with image from Dang et al., 2016
whole organism neoplasm increased amount, abnormal cancer xenotransplantation Fig. 1 from Kim et al., 2017
whole organism neurofibrosarcoma increased amount, abnormal cancer xenotransplantation Fig. 7 with image from Ki et al., 2017
whole organism neurofibrosarcoma increased amount, ameliorated chemical treatment by environment: trametinib, cancer xenotransplantation Fig. 7 with image from Ki et al., 2017
whole organism neurofibrosarcoma increased amount, ameliorated cancer xenotransplantation, chemical treatment by environment: trametinib, chemical treatment by environment: sunitinib Fig. 7 with image from Ki et al., 2017
whole organism neurofibrosarcoma increased amount, ameliorated chemical treatment by environment: sunitinib, cancer xenotransplantation Fig. 7 with image from Ki et al., 2017

CITATIONS  (36)